Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Non-Current Assets (2021 - 2025)

Kiniksa Pharmaceuticals International's Non-Current Assets history spans 5 years, with the latest figure at $236.5 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 4.94% year-over-year to $236.5 million; the TTM value through Dec 2025 reached $957.5 million, down 2.62%, while the annual FY2025 figure was $236.5 million, 4.94% down from the prior year.
  • Non-Current Assets reached $236.5 million in Q4 2025 per KNSA's latest filing, roughly flat from $236.8 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $250.0 million in Q4 2023 to a low of $30.6 million in Q2 2022.
  • Average Non-Current Assets over 5 years is $175.3 million, with a median of $231.7 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: decreased 10.93% in 2022, then skyrocketed 677.77% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $36.4 million in 2021, then soared by 495.84% to $216.6 million in 2022, then grew by 15.43% to $250.0 million in 2023, then fell by 0.51% to $248.8 million in 2024, then fell by 4.94% to $236.5 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Non-Current Assets are $236.5 million (Q4 2025), $236.8 million (Q3 2025), and $240.8 million (Q2 2025).